Explore news & insights from us

Clinical Adoption Roadmap: How to Get Hospitals and Physicians to Use Your Product

A Corrective and Preventive Action (CAPA) system is a critical component of quality management in medical device manufacturing. Required by ISO 13485, FDA 21 CFR Part 820, and EU MDR, CAPA ensures that manufacturers systematically identify, analyze, and eliminate quality issues to prevent recurrence. A well-executed CAPA system improves product safety, enhances compliance, and reduces risks associated with defective medical devices.

The European Union's Medical Device Regulation (EU) 2017/745 (MDR) has established a stringent regulatory framework, superseding the former Medical Device Directive (MDD 93/42/EEC) and imposing significantly higher requirements for clinical evidence, technical documentation, and post-market surveillance. For complex medical devices, particularly those incorporating Software as a Medical Device (SaMD), navigating this compliance pathway demands a systematic, expert-led strategy. This analysis delves into the inherent constraints of the MDR compliance process, clarifies realistic timelines, and details the complexities of integrating technical standards. Furthermore, it analyzes the role of a specialized technology partner, such as ITR, in successfully navigating and executing this intricate pathway.

Design for Manufacturability (DFM) is a proactive engineering approach that optimizes medical device designs for efficient, cost-effective, and scalable production. By considering manufacturing constraints early in the design process, companies can reduce production costs, minimize defects, and accelerate time to market while ensuring compliance with FDA, ISO 13485, and EU MDR standards

Bringing a MedTech or IoT device from concept to market requires structured development phases. Each stage—PoC, prototype, Alpha, Beta, DVT, DFM, pilot, and mass production—serves a critical purpose in ensuring functionality, manufacturability, and compliance.

CROs are rapidly integrating AI, cloud platforms, wearables, and blockchain to optimize clinical trials. By adopting risk-based monitoring, decentralized trials, and real-time data analysis, CROs can reduce costs, accelerate approvals, and improve patient outcomes. The future of clinical research lies in digital transformation, ensuring faster and more efficient trials for new medical innovations.

Real-World Evidence (RWE) is transforming the way medical devices, digital health solutions, and pharmaceuticals gain regulatory approval and market adoption. Unlike traditional clinical trials, which are conducted in controlled environments, RWE is derived from real-world data (RWD), including patient health records, insurance claims, and wearable device monitoring. For MedTech startups, leveraging RWE is essential for proving clinical effectiveness, securing regulatory approvals, and demonstrating value to payers and healthcare providers

Fast Healthcare Interoperability Resources (FHIR) has revolutionized the way healthcare systems exchange data. Developed by HL7, FHIR provides a standardized, web-based approach to interoperability, enabling seamless communication between electronic health records (EHRs), medical devices, and digital health applications.

One of the biggest challenges in AI regulatory approval is the lack of standardized transparency metrics across different regions. While agencies like the FDA (U.S.), EMA (Europe), and NMPA (China) all require Explainable AI (XAI) for high-risk medical applications, they do not yet have unified criteria to measure AI transparency and interpretability.